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Histones control gene expression by regulating chromatin structure and function. The
posttranslational modifications (PTMs) on the side chains of histones form the epigenetic
landscape, which is tightly controlled by epigenetic modulator enzymes and further recog-
nized by so-called reader domains. Histone microarrays have been widely applied to inves-
tigate histone–reader interactions, but not the transient interactions of Zn2+-dependent
histone deacetylase (HDAC) eraser enzymes. Here, we synthesize hydroxamic acid-modified
histone peptides and use them in femtomolar microarrays for the direct capture and
detection of the four class I HDAC isozymes. Follow-up functional assays in solution provide
insights into their suitability to discover HDAC substrates and inhibitors with nanomolar
potency and activity in cellular assays. We conclude that similar hydroxamic acid-modified
histone peptide microarrays and libraries could find broad application to identify class I
HDAC isozyme-specific substrates and facilitate the development of isozyme-selective
HDAC inhibitors and probes.
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The human genetic code is stored in nucleosome particles,supramolecular assemblies of DNA wrapped around his-tone octamers, which comprise two copies of each of the
core histone proteins H2A, H2B, H3, and H41. Epigenetic marks
in the form of posttranslational modifications (PTMs) to histone
amino acid side chains critically affect chromatin structure and
ultimately gene expression2,3. Aberrant gene expression is directly
associated with cancer, autoimmune deficiencies, and neurode-
generative diseases and may be modulated by altering the epi-
genetic state of the cell2–5. This epigenetic state is highly dynamic
and responds to a variety of external stimuli of the cell such as
nutrient composition and stress, but also at a systemic level to
diet, lifestyle, environment, and, importantly, pharmaceutical
intervention2,4. Therefore, a detailed understanding of the
enzymes that shape the histone PTM landscape is of great
interest. Peptide microarrays have been widely employed for the
characterization of histone reader domains as well as histone-
modifying enzymes and antibodies6–13. Also, chemical protein
and peptide synthesis have facilitated the incorporation of mod-
ified amino acids to decipher how specific histone PTMs (e.g.,
acetylation, methylation, phosphorylation, ubiquitylation, and
citrullination) affect recognition and chromatin structure at the
molecular level14. One component of this complex, dynamic
regulatory machinery is the reversible acetylation of the ε-amino
group of lysine residues, which is regulated by histone acetyl-
transferases (HATs) and histone deacetylases (HDACs 1–11;
Fig. 1a)15,16. Further, the resulting ε-N-acetyllysine (Kac) mark is
specifically recognized through bromodomains, constituting an
important class of reader domains5. Peptide microarray strategies
have proven valuable for providing binding affinities of large
numbers of peptides17,18, and have especially proven efficient for
interrogating the specificity of epigenetic reader domains6,7,9,11,12.
Compared to HATs and bromodomains8–10,13, however, the
application of peptide microarrays to the investigation of HDACs
has remained more challenging19–22. The fast turnover of acetylated
substrates and the resulting transient HDAC–substrate interaction
necessitated coupling of the conventional peptide microarray
approach with a secondary readout, such as radioactive isotopes23,
fluorescence tags24,25, immunodetection of the resulting acetylation
states21,22,26,27, or mass spectrometry19,20,28,29. Despite these efforts,
the understanding of the inhibitor and substrate selectivity of the
human Zn2+-dependent HDAC isoforms is still incomplete. This is
particularly true for class I HDACs (HDACs 1‒3 and 8, Fig. 1a),
which are the HDAC isozymes primarily targeted by clinically-used
drugs30,31 and responsible for histone deacetylation16.
Here, we report the synthesis and application of peptide
microarrays that circumvent the aforementioned limitations by
the introduction of hydroxamic acid-containing residues in place
of the Kac residues (Fig. 1b)32–34, which thereby provide a plat-
form to investigate HDAC binding preferences in high-
throughput (Fig. 1c). Complementary functional assays evaluate
the ability of this approach to predict HDAC binding, inhibition,
and activity.
Results
Modified peptides enable interrogation of HDAC binding in
microarray format. Conventional display of acetylated peptides in
microarray format does not allow studying HDAC binding due to
the fast turnover and resulting transient HDAC‒peptide interaction.
We envisioned that modifying acetylated peptides similar to common
competitive inhibitors of class I HDACs could enable the capture and
detection of HDACs in microarray format. The cap group of such
inhibitors interacts with the enzyme surface close to the catalytic
pocket and the linker projects a zinc-binding group through a
channel to the Zn2+ ion in the active site (Fig. 2a)31,32. Consequently,
the turnover of Kac-containing peptides by Zn2+-dependent HDACs
can be inhibited by entities where the Kac has been substituted
with zinc-binding groups, and peptides containing the hydroxamic
acid32–34 or the o-aminoanilide35 functionalities have been shown to















































































Fig. 1 Hydroxamic acid-modified microarrays for the direct capture and detection of class I HDAC isozymes. a Phylogenetic relationship of the 11 human
Zn2+-dependent HDACs. b X-ray co-crystal structures showing the binding pocket of HDAC8 interacting with a Kac-containing peptide substrate or a
hydroxamic acid. In contrast to Kac (left, PDB: 5DIC, Y306F mutation required for deactivation), hydroxamic acids (right, PDB: 3EW8) stall the transient
interaction by chelating the Zn2+ ion in the active site. c Workflow. Peptide microarrays are prepared using the appropriate hydroxamic acid-containing
aminosuberic acid analog (Asuha). Resulting arrays allow for the direct assessment of HDAC isoform-specific binding. Kme1, Kme2, Kme3: ε-N-mono-, di-,
and trimethyllysine; pS: O-phosphoserine; pT: O-phosphothreonine; Kac: ε-N-acetyllysine.
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these moieties in histone tail peptide microarrays to interrogate
the binding of class I HDACs. Modified peptide microarrays
were produced using µSPOT, a variant of the widely applied
SPOT method36–38. We found that replacing lysine residues in his-
tone sequences by L-2-amino-8-(hydroxyamino)-8-oxooctanoic
acid (Asuha) or L-2-amino-8-((2-aminophenyl)amino)-8-oxoocta-
noic acid (Asuapa) but not L-2-aminosuberic acid (Asu) or acetylated
lysine (Kac) efficiently captured the HDAC–substrate interaction
(Fig. 2b). Both Asuha and Asuapa provided sequence-dependent
binding results, and Asuha was selected for further investigations due
to the higher HDAC retention shown by the corresponding peptides.
The length of the histone-based peptides was chosen to be 15 resi-
dues, because the synthetic efficiency of the µSPOT method decreases
substantially above the 15–16-mer length. Our findings were in line
with the observation that class I-selective o-aminoanilides, such as the
approved drug chidamide and the clinical trial candidate entinostat,
are among the most potent inhibitors, only surpassed by less selective
hydroxamic acid-containing compounds such as panobinostat31.
We next envisioned that hydroxamic acid-modified peptide
microarrays would enable the direct and simple interrogation of
HDAC isozyme binding and, potentially, facilitate the develop-
ment of isozyme-selective inhibitors and probes (Fig. 1c). The
implementation of this technique required an improved synthetic
route for the Asuha building block. Modification of an
acetamidomalonate alkylation/enzymatic resolution strategy39,40
provided an affordable and scalable synthetic route for Fmoc-
Asuha(tBu)-OH (2 g, 20% overall yield, Supplementary Fig. 1)
compared to previously reported syntheses33,34,41. Hydroxamic
acid-modified µSPOT arrays were then produced and successful
synthesis of the modified peptides was validated by LC-MS
analysis of a subset of crude peptides prior to printing of the
microarrays (Supplementary Table 1). Unfortunately, the crude
peptides could not be triturated before chromatography due to
the minute amounts produced and the resulting HPLC traces,
therefore, included protecting group byproducts. Nevertheless, an
average purity of 41%, corresponding to average coupling
efficiency of at least 95%, was observed, which is in line with
standard SPOT42,43 and µSPOT44 peptide synthesis. The
detection of a dilution series of His-tagged HDAC2 spotted on
a µSPOT slide indicated a linear correlation between signal and
spotted amount (Supplementary Fig. 2, r2= 0.96) when a
horseradish peroxidase (HRP)-conjugated anti-His antibody was
used. Thus, taken together, the µSPOT method allowed for
economic production of hundreds of microarray copies from a
single round of synthesis and thereby facilitated the semi-
quantitative assessment of HDAC isozyme–peptide interactions
(Fig. 1c)37,38.
Microarray-based screening and fine mapping of class I HDAC
interactions. Next, we explored the use of hydroxamic acid-
modified microarrays to study class I HDAC substrate recogni-
tion. We displayed a library of 291 histone-based peptides (16
amino acids in length and with a 3-residue frameshift) with the
Asuha building block at the position of one lysine residue at a
time, in order to comprehensively and systematically study
recognition of the four core histones by HDACs 1‒3 and 8
(Supplementary Table 2). Microarray copies were titrated with
recombinant human His-tagged class I HDACs and binding was
detected with an anti-His antibody as before.
The recapitulation of known binding sites demonstrated the
robustness of our platform. As expected, only peptides including
Asuha residues were able to enrich HDACs. At the same time, we
observed striking differences in isozyme affinity and selectivity
(Fig. 3). HDACs 1, 2, and 8 displayed high sequence specificity, in
agreement with previous substrate selectivity studies on
HDAC828,45, and also similar to HDAC622. In contrast, HDAC3
bound more promiscuously and to sequences located both at the
core and the tails of the histones. This might indicate that
HDAC3 is less sensitive to the peptide sequence, as also reported
for short peptide substrates46,47 and acetylated peptide micro-
arrays20. Sequence logo plots were generated to highlight the
amino acid preferences of each HDAC (Supplementary Fig. 3).
These plots revealed an overall preference for Arg and Lys



































































































Fig. 2 Zinc-binding groups allow probing HDACs in microarray format. a Approved drugs and examples of candidates in clinical trials that target class I
HDACs31. Shared features include a cap group, a hydrophobic linker region, and zinc-binding group. b Display and probing of modified 15-mer histone
peptides for capture of HDAC3 (10 nM) on microarray slides. Incorporation of a 2-aminosuberic acid hydroxamic acid derivative (Asuha) or a 2-
aminosuberic acid o-aminoanilide derivative (Asuapa) but not the carboxylic acid (Asu) allow probing of HDAC binding in microarray format (n= 2
independent experiments). Source data are provided as a Source Data file. *Saturated chemiluminescence signal.
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Fig. 3 Screening of class I HDAC‒histone peptide binding in microarray format. Heat map representation of relative HDAC binding affinity for Asuha (X)-
containing histone peptides. The pEC50 values represent the concentration of HDAC enzyme required for half-maximal binding signal (n=4 independent dose-
response experiments). White squares represent weak binders (pEC50 < 7.6). N.D.= not determined (non-sigmoidal data). Source data are provided as a Source Data
file. *HDAC3 tested in combination with the deacetylase activating domain (DAD) of NCoR2. †Matrix steric effects might impede protein binding to these peptides.
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residues at the positions flanking the Asuha residue for all class I
HDACs, which was previously observed for HDAC828 and, to
some extent, also HDAC320. Interestingly, HDAC6 shows the
opposite preference22. Further class I HDAC selectivity was
observed for sequences containing Gly at the -2 and -3 positions,
and Arg and Lys at the −4, +3, and +4 positions. Not
surprisingly, histone tails are rich in Arg, Lys, and Gly residues,
which could explain the obtained sequence preference. In this
regard, we expect that future evaluation of potential isozyme-
specific preferences would benefit from the use of randomized
peptide arrays.
The microarrays were also applied for mapping binding sites
with semi-quantitative estimation of binding affinities. This was
outlined for histone H4 lysine 12 (H4K12) (Fig. 4a). Titration of
single amino acid frame-shifted peptides and single amino acid
truncation variants suggested exact binding sites and indicated
that the C-terminus of the selected peptide is required for binding
to HDACs 1, 2, and 8 (Supplementary Figs. 4‒7). Peptides 1a‒5a
were then synthesized, purified, and tested as HDAC inhibitors to
validate these observations. Peptides 4a and 5a showed 10-fold
lower potency than the parent peptide (1a), as suggested by the
data on HDACs 2 and 8, but not HDAC1 (Fig. 4c and
Supplementary Fig. 8). More strikingly, peptides 2a and 3a with
C-terminal truncations retained potency against all HDACs. This
could indicate that particularly HDACs 1, 2, and 8 are sensitive to
the steric effect of the microarray matrix and struggle to bind to
Asuha residues closer than 5 amino acids to the C-terminal peptide
conjugation site. On the other hand, HDAC3 was not affected by
this effect, which could also explain the higher rate of positive
results for this isozyme. Overall, the mapping of the H4K12 site
revealed a complex sequence requirement for HDACs 1, 2, and 8,
especially for residues within ±7 positions relative to the acetylated
lysine. This mapping highlighted the importance of steric effects
introduced by the immobilization and thus the importance to
validate results with resynthesized peptides in solution.
Microarray-based study of the binding effects of posttransla-
tional modifications. The action of epigenetic modulators,
including HDACs, is orchestrated by PTMs48. We next applied
our microarray approach to resolve how specific PTM combina-
tions control isozyme-specific class I HDAC function. To probe
this, we selected two H3 N-terminal peptides for modification in a
combinatorial manner according to reported histone PTMs
(Supplementary Table 4)48,49. The included modifications were O-
phosphoserine (pS), O-phosphothreonine (pT), ε-N-mono-, di-,
and trimethyllysine (Kme1, Kme2, and Kme3, respectively), Kac,
and ε-N-thioacetyllysine (Kthioac), which is a Kac analog with
enhanced stability towards hydrolases50,51 that is only cleaved to
some extent by HDACs 6 and 852 and class I sirtuins53.
Remarkably, the microarray approach resolved complex and
highly isozyme-specific binding profiles (Fig. 5a). Importantly,
binding of HDACs to H3 peptides was diminished by phos-
phorylation of residues Ser10 or Thr11. Conversely, enrichment of
HDACs 1, 2, and 8 was improved by modification of the Lys4 and
Thr6 residues. Modifications at Lys23 also diminished HDAC8
binding, although its proximity to the C-terminus makes it diffi-
cult to interpret this trend due to the aforementioned matrix steric
effects. Notably, the pronounced effect of phosphorylation of
H3S10 in the microarray may mirror an altered recognition by
epigenetic enzymes shown to play a pivotal role in the histone
modification cross-talk54,55. To further validate the prediction of
HDAC isozyme substrate recognition and selectivity, we studied
deacetylation of resynthesized peptides modified at the Lys4 and
Ser10 residues. Thus, H3 sequences were prepared as Kac-
modified peptides with and without thioacetylation and phos-
phorylation by standard Fmoc/tBu SPPS (Fig. 5b) and were
incubated with recombinant class I HDACs. Substrate conversion
was followed by LC–MS analysis, which revealed that Ser10
phosphorylation, as predicted by the microarray, decreased the
deacetylation by HDACs, whereas Lys4 thioacetylation did not
promote conversion by HDACs 1, 2, and 8 (Fig. 5b and Supple-
mentary Fig. 9). Taken together, our results highlight the applic-
ability of hydroxamic acid-modified microarrays to interrogate
changes in HDAC substrate that give rise to substantially
altered recognition in high-throughput. In particular, we
demonstrated that these microarrays may help identify individual
positions and specific PTMs that critically alter peptide binding
affinity and isozyme selectivity; thus, providing a useful tool to
study HDAC function and its regulation.
Identification of potent HDAC inhibitors with tailored iso-





































































































Peptide  Sequence  
1a: H4(5–19)K12Asuha Ac-KGGKGLGXGGAKRHR-W-NH2 
2a: H4(1–15)K12Asuha Ac-SGRGKGGKGLGXGGA-W-NH2 
3a: H4(5–14)K12Asuha     Ac-KGGKGLGXGG-W-NH2 
4a: H4(9–23)K12Asuha         Ac-GLGXGGAKRHRKVLR-W-NH2 
5a: H4(10–19)K12Asuha      Ac-LGXGGAKRHR-W-NH2 
Fig. 4 Application of hydroxamic acid-modified peptide microarrays for
mapping peptide binding requirements. a Fine mapping of relative HDAC1
binding affinities in microarray format (data represent mean ± SEM, n= 4
independent experiments). See Supplementary Figs. 4‒7 for complete data
sets for HDACs 1‒3 and 8. X: Asuha. Source data are provided as a Source
Data file. b Resynthesized peptide sequences including the parent peptide
(1a), two frame-shifted sequences (2a, 4a), a C-truncated sequence (3a),
and a N-truncated sequence (5a). c Comparison of the inhibitory curves of
resynthesized peptides 1a‒5a with their corresponding microarray binding
curves against HDAC1 (microarray data represent mean ± SEM, n= 4
independent experiments; inhibition data represent n= 2 independent
experiments). See Supplementary Fig. 8 for data on HDACs 2, 3 and 8 and
for half-maximal inhibition concentrations. Source data are provided as a
Source Data file.
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I HDACs (HDACs 1‒3 and 8) have been reported, some of which
are approved for clinical use30,31. The majority are small mole-
cules bearing a hydroxamic acid moiety, which exhibit limited
isozyme selectivity. Microarray screening (Figs. 3 and 5) identi-
fied modified peptides with potential isozyme selectivity and
suggested that even small chemical modifications can exert strong
and isozyme-selective effects on HDAC recognition. To validate
the reported selectivity and to quantify their inhibitory potency
towards class I HDACs, we resynthesized additional nine
hydroxamic acid-containing peptides (9a–17a) from the initial
screen and evaluated HDAC inhibition in an in vitro fluorogenic
assay56,57. All tested peptides displayed robust nanomolar
potency against HDACs 1‒3, and also against HDAC8 in the case
of peptides 6a, 13a, and 14a (Fig. 6a and Supplementary Fig. 10).
As expected, control peptides with a lysine residue instead of
Asuha did not inhibit any of the tested HDACs, even at high
micromolar concentration.
The determined inhibitor profiles confirm the potency of
multiple hits and validate the concept that peptide scaffolds can
achieve isozyme selectivity, but they also reveal that potent
inhibitors may be overlooked during microarray screening.
Sequences 11a, 12a, and 13a exhibited selectivity for HDAC3
in the microarray (Fig. 3). For the resynthesized peptides, we
found ~4-fold, ~2-fold, and >8-fold selectivity for HDAC3 vs.
HDACs 1 and 2, respectively (Fig. 6c, d), which supports the use
of our screening technique to discover selective lead inhibitors.
Peptide 11a was also >60-fold selective for HDAC3 vs. HDAC8,
whereas peptide 13a inhibited HDAC8 potently, which was not
anticipated. Interestingly, peptides 9a and 16a displayed over
100-fold selectivity against HDACs 1‒3 versus HDAC8 (Fig. 6c,
d), which is uncommon among hydroxamic acid-containing
inhibitors57. Conversely, peptide 14a inhibited all four isozymes
with similar potency, in agreement with the microarray data
(Figs. 3 and 6d). The cytosolic isozyme HDAC6 was also included
in the profiling because it is inhibited by several known
hydroxamic acid-containing HDAC probes57. Peptides 1a and
15a were the most and least potent inhibitors against this
isozyme, respectively (1a: Ki= 5.31 ± 0.03 nM, 15a: Ki= 114 ± 2
nM, Supplementary Fig. 11a). As expected, the inhibitors were
highly selective over class IIa HDACs, represented by HDAC4,
which was only partially inhibited at inhibitor concentrations of
up to 50 µM (Supplementary Fig. 11b).
Though a number of the potencies recorded for resynthesized






















































b Peptide  Sequence  
6c: H3(1–16)K9ac Ac-ARTKQTARK(ac)STGGKAP-W-NH2 
7c: H3(1–16)K4thioac,K9ac Ac-ARTK(thioac)QTARK(ac)STGGKAP-W-NH2 
8c: H3(1–16)K4thioac,K9ac,pS10 Ac-ARTK(thioac)QTARK(ac)(pS)TGGKAP-W-NH2 
 HDAC1 




6a/c < 7.2  50.2 ± 0.1 
7a/c 8.3 ± 0.2  47 ± 1 






  7.3 ± 0.1  60.7 ± 0.5 
  7.76 ± 0.04  53.7 ± 0.6  






8.55 ± 0.05  22 ± 3 
8.57 ± 0.07  32.8 ± 0.4 






7.75 ± 0.09  7.5 ± 0.3  
8.08 ± 0.09  5.3 ± 0.3  
< 7.2  1.4 ± 0.1 
Fig. 5 Deciphering the regulation of HDAC action by histone PTMs. a Heat map depicting effects of neighboring chemical modifications on the affinity of
peptides H3(1‒16)K9Asuha and H3(10‒25)K18Asuha. p: phosphorylation, ac: acetylation, thioac: thioacetylation, me1: monomethylation, me2:
demethylation, me3: trimethylation. Combinations of 4, 5, and 6 modifications abolished binding to H3(1‒16)K9Asuha peptides and have not been
included. The pEC50 values represent the concentration of HDAC enzyme required for half-maximal binding signal, n= 4 independent experiments). White
squares represent weak binders (pEC50 < 7.2). Source data are provided as a Source Data file. b Resynthesized peptide sequences with Kac at the position
of study, and relative deacetylation by class I HDACs. Enzyme and substrate were incubated for 1 h at 37 °C, and relative conversion was determined by
LCMS (see Supplementary Fig. 9 for sample assay traces). Microarray data represent mean ± SEM, n= 4 independent experiments; conversion data
represent mean ± SD, n≥ 2 independent experiments. *HDAC3 tested in combination with the DAD domain of NCoR2. †Matrix steric effects might
contribute to the effects at these positions.
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number of the weaker binders were not estimated accurately in
the microarray screening, thereby highlighting the need for
detailed follow-up validation when applying this technology
(Supplementary Fig. 12). Peptides 13a and 17a, which appeared
to exhibit preference for HDACs 2 and 3 over HDAC1 in the
array experiments, were both equipotent across all three
recombinant HDACs 1–3, when tested in solution. This high-
lighted once more the importance of sufficient C-terminal
spacing in microarray format, as both peptides included the
Asuha residue within 5 amino acid positions of the linker. In
addition, peptide 11a, which was among the most potent
inhibitors of HDACs 1 and 2, did not show tight binding on
the array for these two isozymes. Nevertheless, microarray
screening enabled the discovery of potent peptide scaffolds with
distinct profiles of HDAC inhibition. Additionally, our data
confirmed a major contribution of the peptide sequence to
substrate turnover, inhibitor potency, and isozyme selectivity
(Fig. 6d and Supplementary Fig. 13), indicating that peptide
scaffolds are an appropriate source for isozyme selective
inhibitors and affinity probes.
Hydroxamic acid-modified peptides exhibit activity in cells.
Next, we aimed to explore the cellular activity of selected HDAC
inhibitors. We chose peptides 1a and 13a, which exhibit nano-
molar potency against class I HDACs and HDAC6 and, at the
same time, harbor multiple basic residues that could facilitate cell
permeation. HEK293T cells were treated with the peptides for 5 h,
and subsequent cell lysis and Western blot analysis revealed
upregulation of acetylation of both tubulin and histones com-
pared to DMSO control (Fig. 7a). These results strongly indicate
that peptides 1a and 13a effectively inhibit the cytosolic HDAC6
Fig. 6 Identification of potent HDAC inhibitors with distinct selectivity profiles. a Dose-response HDAC inhibition curves for Asuha (X)-containing
peptides (9a‒13a), the HDAC inhibitor SAHA and lysine-containing controls (9b‒13b). See Supplementary Fig. 10 for curves corresponding to 6a, 14a‒17a,
and corresponding controls. b Sequence of resynthesized peptides. c Dose-response curves for peptides 11a, 13a, 14a, and 16a. d Summary of microarray
screening data and the determined potency of resynthesized Asuha-containing peptides in solution. See Supplementary Fig. 12 for visual representation.
*HDAC3 tested in combination with the DAD domain of NCoR2. All microarray data represent mean ± SEM, n= 4 independent experiments; all inhibition
data represent n= 2 independent experiments. Source data are provided as a Source Data file.
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and the nuclear HDACs 1‒3 in the cell, which is in agreement
with their in vitro inhibition profiles against recombinant
HDACs15. In particular, peptide 13a induced an 8-fold increase
in tubulin acetylation and a 4-fold increase in H3K36 acetylation
(Fig. 7b). Thus, the high-throughput screening and subsequent
evaluation in solution delivered cellularly active HDAC probes.
Discussion
Peptide microarrays are broadly applied to study writers and readers
of histone modifications6,7,9,11,12, especially bromodomains8–10,13.
Their application to erasers of histone acetylation, however, has
remained limited to activity-based approaches, as microarray binding
experiments required secondary readouts19–29. In addition, activity-
based approaches rely on antibodies specific for a certain peptide
modification, which can sometimes lead to biases induced by the
sequence context. Here, we describe a facile, cost-effective, and
scalable protocol for the preparation of the necessary hydroxamic
acid building block and demonstrate its use to produce hydroxamic
acid-modified peptide microarrays. These arrays allow the simple and
direct profiling of HDAC binding and inhibition with minimal
sample consumption and with the use of extensively validated tag-
specific antibodies. When used systematically, similar arrays could
provide large data sets and answer fundamental questions related to
HDAC action and its regulation. Here, we demonstrated the use of
this format to identify individual positions and modifications that
determine isozyme-specific binding, and to the discovery of cellularly
active peptides with tailored HDAC selectivity.
Hydroxamic acid-modified peptides have been used as sub-
strate mimics and were shown to recapitulate important aspects
of HDAC substrate recognition32–34,58. Here, we systematically
explored the sequence and PTM requirements for the recognition
of histone tails, as represented by Asuha-modified peptides, by
HDACs 1, 2, 3, and 8. Our extensive dataset will enable future in-
depth investigation of specific PTM effects on HDAC activity.
These follow-up studies would benefit from the use of synthetic
histones and reconstituted nucleosomes, which can reveal
sequence effects beyond the length limitations of synthetic
peptides45,58.
Selected inhibitor candidates displayed nanomolar potency and
distinct selectivity profiles. Yet, the binding hierarchies in the
screens did not represent the exact inhibitor selectivity profiles
defined by more accurate in-solution assays. The potency of
peptides with the Asuha residue close to the C-terminus was not
well predicted, likely due to steric interference of the microarray
matrix, and a number of additional potent inhibitors were over-
looked by microarray screening. Kinetic insight from peptide
macrocycles59 and an X-ray co-crystal structure of HDAC1 with a
hydroxamate-containing H4-based peptide32 suggest that Asuha-
containing peptides bind in the active site. Nonetheless, future
studies should explore to what extent HDAC substrate turnover
correlates with inhibitor potency or selectivity. This question
could be addressed using the approach presented herein, together
with alternative modifications such as the here described Asuapa
building block. Such studies should take into account isozyme-
specific effects, kinetic parameters, and contributions from
additional binding partners60. Moreover, incubation with
recombinant HDACs bearing active site mutations or co-
incubation with validated HDAC probes could improve the
selection of competitive inhibitor candidates from the array
screening.
Selected microarray hits proved to penetrate the cell membrane
and elicit hyperacetylation of class I and class IIb HDAC targets.
Thus, combined with structural optimization such as stapling
and/or N-methylation61,62, promising peptide-based HDAC
probes could be afforded. The approach presented here could also
be applied to the study class IIa HDACs, taking advantage of
trifluoromethyl ketone-containing building blocks63, and deace-
tylase enzymes from other species64–67. The HDAC probes here
reported may be the first of a new class of versatile tools for
investigating class I HDACs and, importantly, also their native
protein complexes33.
Further, the employed principle may be applied to alternative
peptide microarray types including high-density lithography68
and laser-based on-chip synthesis approaches69,70, thereby fur-
ther increasing the throughput. In addition, alternative binding
detection methods could improve the dynamic range of the
screening assay and potentially enhance the predictive value of
the array18. Probing such microarrays with cellular lysates, using
labeled HDACs and complex partners or highly specific anti-
bodies, may provide a direct readout for the substrate-binding
requirements of the native complexes16. Combination of such
readout with different cells and tissues, as well as with perturbed
HDAC levels, could greatly improve our current understanding of
HDAC action in vivo.
Finally, we envision that the current approach can facilitate the
development of selective chemoproteomic probes that would
complement the already applied unspecific HDAC-targeting
probes71–73. We expect that this work will enable the discovery,
characterization, and selective targeting of cellularly active and,
potentially, therapeutically relevant multiprotein complexes
formed by the different HDAC isoforms16.
Methods
Chemical Synthesis. General synthetic methods, experimental procedures, and
compound characterization can be found in the Supplementary Methods.
Assay Materials. Assays were performed in 4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid (HEPES) buffer [50 mM HEPES/Na, 100 mM KCl,
0.001% (v/v) tween-20, 0.2 mM tris(2-carboxyethyl)phosphine (TCEP), 0.5 mg/mL
bovine serum albumin (BSA), pH 7.4] unless otherwise stated. Recombinant
HDAC enzymes employed in µSPOT, inhibitor, and substrate assays were from
commercial sources: HDAC1 (full length, C-terminal His tag, C-terminal FLAG
tag, BPS Bioscience, cat. #: 50051, lots 170105-1 and 181108-1, purity ≥ 79%,
activity ≥ 460 pmol/min/µg), HDAC2 (full length, C-terminal His tag, BPS
Bioscience, cat. #: 50002, lots 160701 and 160630, purity ≥ 84%, activity ≥ 675
pmol/min/µg), HDAC3/NCoR2 (full length, C-terminal His tag, NCoR2
N-terminal GST tag, BPS Bioscience, cat. #: 50003, lots 130819 and 190327, purity
≥ 80%, activity ≥ 3000 pmol/min/µg), HDAC8 (full length, C-terminal His tag, BPS













































































Fig. 7 Inhibition of HDACs in cultured cells. a Sample Western blots on
tubulin acetylation (Ac-α-tubulin) and histone acetylation (H3K27, H3K36)
upon 5 h treatment with peptides 1a and 13a at 10 µM concentration, with
SAHA as positive control (Ac-α-tubulin: 1 µM; H3K27ac, H3K36ac: 5 µM).
See Supplementary Fig. 14 for full blots of all replicates. b Quantification of
acetylation, normalized to vinculin loading control, and relative to DMSO
(data represent mean ± SD, n= 4 biologically independent samples).
Source data are provided as a Source Data file.
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pmol/min/µg), HDAC4 (aa 627‒1084, BPS Bioscience, cat. #: 50004, lot 130828-G,
purity ≥ 89%, activity ≥ 103225 pmol/min/µg), HDAC6 (full length, BPS
Bioscience, cat. #: 50056, lot 151130-C, purity ≥ 88%, activity ≥ 150 pmol/min/µg).
Antibodies: 6x-His tag monoclonal antibody (HIS.H8), HRP-conjugated (Ther-
moFisher, cat. #: MA1-21315-HRP).
µSPOT Microarray Preparation. Peptides were synthesized using a ResPep SL
synthesis robot equipped with a CelluSPOT synthesis module (Intavis AG, Germany).
Parallel synthesis was carried out on acid-soluble Fmoc-β-Ala-etherified cellulose disks
(area 0.12 cm2, loading 1.0 μmol/cm2, Intavis AG), by Fmoc/tBu peptide synthesis on
cellulose support (SPOT synthesis). The following protected amino acids were
employed: Fmoc-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Asu(tBu)-OH39, Fmoc-Asuapa
(Boc)-OH (S8), Fmoc-Asuha(tBu)-OH (S5), Fmoc-Asn(Trt)-OH, Fmoc-Asp(OtBu)-
OH, Fmoc-Cys(Trt)-OH, Fmoc-Gln(Trt)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Gly-OH,
Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Ac)-OH, Fmoc-Lys(Me,
Boc)-OH, Fmoc-Lys(Me)2-OH, Fmoc-Lys(Me)3-OH, Fmoc-Lys(thioac)-OH, Fmoc-Lys
(Boc)-OH, Fmoc-Pro-OH, Fmoc-Ser(tBu)-OH, Fmoc-Ser(PO3BzlH)-OH, Fmoc-Thr
(tBu)-OH, Fmoc-Thr(PO3BzlH)-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH and
Fmoc-Val-OH. Peptide elongation was achieved by double coupling in DMF (20 and
15min) with Fmoc-Xaa-OH/Oxyma/DIC (1.0:1.1:1.5 equiv) in at least 2-fold excess,
followed by capping with acetic anhydride. Functionalized cellulose disks were trans-
ferred to 1.2mL 96-tube racks (Intavis AG, cat. # 32.199) and shaken with
TFA–CH2Cl2–H2O–iPr3SiH, [150 µL, 80:12:5:3 (v/v)] for 2 h at room temperature.
Solutions were then removed, and disks were suspended in TFA–CF3SO3H–H2O–
iPr3SiH [250 µL, 88.5:4:2.5:5 (v/v)] and shaken overnight at room temperature.
Thereafter, solutions were triturated with ice-cold diethyl ether (700 µL), stored at
−20 °C for 2 h and centrifuged at 1000 rcf (45min, 4 °C). Supernatants were discarded,
and pellets were rinsed with diethyl ether in the same manner. Then, 96-tube racks were
ventilated for 2.5 h to allow for residual diethyl ether to evaporate, and pellets were
dissolved in DMSO (500 µL) and stored at −20 °C. µSPOT microarrays were prepared
by printing DMSO Stock/SSC buffer mixtures (30 nL, 2:1, saline sodium citrate buffer:
15mM sodium citrate, 0.1M NaCl, pH 7) in duplicate on polystyrene-coated micro-
scope glass slides (Intavis AG, cat. # 54.112) with a Slide Spotter Robot (Intavis AG).
Analysis of Cleavable µSPOT Peptides. Disks containing Rink amide linkers
were incubated in 1.5 mL plastic tubes with TFA–2,2′-(ethylenedioxy)diethanethiol
(DODT)–H2O–iPr3SiH [250 µL, 92.5:2.5:2.5:2.5 (v/v)] for 2 h at room temperature.
Solutions were transferred to new plastic tubes, triturated with ice-cold diethyl
ether (750 µL), stored at –20 °C for 1 h and centrifuged at 17968 g (30 min, 4 °C).
Thereafter, supernatants were discarded and pellets were rinsed again with ice-cold
diethyl ether (750 µL). Plastic tubes were ventilated to allow for pellets to dry, and
these were suspended in CH3CN/H2O [50 µL, 50:50 with 0.1% TFA (v/v)]. Analysis
was performed by MALDI (1 µL), UPLC-MS (5 µL) and HPLC (15 µL).
Microarray Spotting of HDACs 2 and 3 and Assay Linearity Test. His-tagged
HDAC2 and 3 were used at a concentration of 41.4 µM (in 40 mM Tris-HCl pH
8.0, 110 mM NaCl, 2.2 mM KCl, 0.04% (v/v) Tween-20, 20% (v/v) glycerol) and
7.5 µM (in 40 mM HEPES pH 8.0, 110 mM NaCl, 2.2 mM KCl, 20% (v/v) glycerol)
respectively. Proteins were diluted to a concentration of 1 µM in a buffer consisting
of 2/3 (v/v) DMSO and 1/3 (v/v) saline-sodium citrate (SSC) buffer (150 mM NaCl,
15 mM trisodium citrate, pH 7.0). A 1:2 (v/v) serial dilution of HDAC2 and 3 was
prepared in a 384-well plate using a buffer of 2/3 DMSO and 1/3 SSC. Protein
solutions were transferred to polystyrene-coated microscope glass slides (Intavis
AG, cat. # 54.112) with a Slide Spotter Robot (Intavis AG). Slides were incubated in
PBS with 2% (w/v) IGG-free BSA (2.5 mL; 137 mM NaCl, 2.7 mM KCl, 10 mM
Na2HPO4, 1.8 mM KH2PO4, pH 7.4) for 60 min at room temperature. Then, slides
were incubated at room temperature with Anti-6x-His tag antibody (ThermoFisher
Scientific, MA121315, Lot.: UF283577) in PBS with 0.1% BSA (1:5000, 2.5 mL,
15 min), washed with PBS (2.5 mL, 3 × 3 min), incubated with HRP-conjugated
goat anti-mouse antibody (ThermoFisher Scientific, 31430, Lot: UJ293428) in PBS
with 0.1% BSA (1:5000, 2.5 mL, 30 min), and washed with PBS (2.5 mL, 3 × 3 min).
SuperSignal West Femto Maximum Sensitive Substrate was added to the slides
(200 µL; ThermoFisher Scientific), and chemiluminescence signal was recorded in a
c400 imaging system (Azure, Lowest Sensitivity, 5 min exposure). Binding inten-
sities were evaluated using FIJI including the Microarray Profile addon (OptiNav).
The error range and standard deviation were defined by comparing the intensities
of two individual spots on the array.
Recombinant HDAC µSPOT Assays. µSPOT slides were incubated in HEPES
buffer containing 10 mg/mL BSA (2 × 4mL, 20 min, 25 °C) in 4-well microscope
slide tray plates (MoBiTec GmbH, cat. #: 1145-40) and rinsed with standard
HEPES buffer (3 × 2 mL). Then, slides were incubated with 6 HDAC concentra-
tions (5-fold dilution; Fig. 3: HDAC1: 77‒0.025 nM, HDAC2: 57‒0.018 nM,
HDAC3/NCoR2: 50‒0.016 nM, HDAC8: 56‒0.018 nM; Fig. 5a: HDAC1: 50‒
0.016 nM, HDAC2: 250‒0.016 nM, HDAC3: 50‒0.016 nM, HDAC8: 150‒0.048 nM)
in HEPES buffer (2 mL, 1 h, 25 °C), rinsed (4 × 2 mL), incubated with HRP-
conjugated 6x-His tag antibody (1:10000 in HEPES buffer, 2 mL, 1 h, 25 °C), rinsed
(4 × 2 mL), and developed. Detection was achieved using SuperSignal West femto
maximum sensitivity substrate [ThermoFisher, cat. #: 34095, solution A and B
(300 µL, 1:1)] and a chemiluminescence imaging system (PXi6, Syngene) with 30 s
exposure time and no binning. The 6 slides incubated with different HDAC
concentrations were imaged together in order to obtain data relative to top and
bottom intensity levels. Experiments were performed twice, data were obtained
with Array Analyze software (Active Motif), and data analysis and representation
were performed with the GraphPad Prism 7 software. Outliers were curated
manually and data were fitted to nonlinear regression [log(agonist) vs. response—
variable slope (four parameters)]. Curves with top values outside of the 0.8‒1.2
range, pEC50 values below the studied enzyme concentration range, and incomplete
curves were considered weak binders and color-coded with white squares. Non-
sigmoidal curves were denoted as not determined (N.D.) The pEC50 values were
determined as the concentration of HDAC enzyme required for half-maximal
binding signal. Data presented in manuscript figures are reported with the number
of significant figures allowed by the standard error of the mean (SEM) calculated
for each experiment. The raw data in the Supporting Tables are not adjusted
corresponding to standard error.
HDAC Inhibition Assays. Assays were performed in 96-well plates (Fischer Sci-
entific, cat. #: 3686) in HEPES buffer (final volume: 25 µL/well). Asuha-containing
peptide inhibitors (5-fold dilution series, or 50 µM and 5 µM concentration for
HDAC4) were incubated with enzyme [HDAC1 (0.5‒4 nM), HDAC2 (0.5‒3 nM),
HDAC3/NCoR2 (1 nM), HDAC8 (0.2‒0.5 nM), HDAC4 (0.01 nM) or HDAC6
(0.5‒1 nM)] and substrate [HDACs 1‒3 and 6: Ac-Leu-Gly-Lys(Ac)-AMC (20 µM),
HDACs 4 and 8: Ac-Leu-Gly-Lys(Tfa)-AMC (20 µM and 100 µM, respectively)] for
30 min at 37 °C (AMC: 7-amino-4-methylcoumarin). A solution of trypsin (25 µL,
0.4 mg/mL; final concentration of 0.2 mg/mL) was subsequently added, and the
assay was allowed to develop for 15 min at room temperature. Then, fluorescence
was recorded and analyzed to afford residual enzymatic activity relative to control
wells and, assuming a standard fast-on/fast-off mechanism, IC50 values were
obtained by fitting the resulting data to the dose–response equation with variable
Hill slope (Eq. 1). Inhibition Ki values were obtained by using the Cheng-Prusoff
equation (Eq. 2) and Michaelis-Menten constants as reported (HDAC1: KM=
6 µM, HDAC2: KM= 3 µM, HDAC3: KM= 6 µM, HDAC6: KM= 16 µM, HDAC8:
KM= 190 µM)57. Assays were performed twice with two internal replicates, and
data was analyzed using GraphPad Prism 7 or 8.
vi ¼ vbottom þ
vtop  vbottom





HDAC Deacetylation Assays. Enzyme [HDAC1 (250 nM), HDAC2 (500 nM),
HDAC3/NCoR2 (5 nM) or HDAC8 (250 nM)] and Kac peptide (HDACs 1‒3:
100 µM, HDAC8: 1 mM) were incubated in HEPES buffer (36 µL) in a 96-well plate
for 1 h at 37 °C. Then, a sample from each well (25 µL) was quenched with
CH3OH/HCOOH [94:6 (v/v) 12.5 µL] and analyzed by UPLC-MS. Gradients rising
linearly 0‒10%, 5‒15%, 10‒20%, or 15‒25% during 4 or 9 minutes were employed
for separation of starting material and deacetylated product. Mass spectra were
used for identification of both species, and conversion was calculated by peak
integration at 280 nm. Assays were performed at least twice.
Cell Treatment and Western Blot. HEK293T cells (ATCC), provided by the Pless
lab at the University of Copenhagen, were cultured under a humidified 5% CO2
atmosphere in Dulbecco’s modified Eagle’s medium (DMEM, Thermo Scientific,
cat. #: 11965118) supplemented with 10% (v/v) fetal bovine serum (FBS), 1%
penicillin and 1% streptomycin. Cells were plated into 6-well plates and grown to
80–90% confluency. Treatment with compounds 1a (10 µM), 13a (10 µM), SAHA
(1 µM), or DMSO was performed in the above-mentioned media for 5 h at 37 °C,
after which the media was aspirated, cells were washed with PBS and treated with
lysis buffer (1% Triton X-100, 0.2% SDS and cOmplete EDTA-free protease
inhibitor cocktail, COEDTAF-RO Sigma-Aldrich, in PBS, 150 µL/well). Upon
scraping, lysates were collected in microcentrifuge tubes, sonicated with a Bandelin
Sonopuls mini20 (2 s on, 2 s off, 80% amplitude, 1 min), centrifuged (14000 g,
10 min, 4 °C), and protein concentrations of the supernatants were determined by
the bicinchoninic acid assay (BCA1, Sigma-Aldrich). The concentrations of the
samples were adjusted to the lowest concentration, and 33–54 µg of lysate were
mixed with NuPAGE LDS sample buffer (ThermoFisher, NP0007) and sample
reducing agent (ThermoFisher, NP0004) followed by heating to 95 °C for 10 min.
Samples were then resolved by gel electrophoresis (SDS-PAGE) in NuPAGE gels
(12 wells, 4‒12% Bis-Tris, 1.0 mm, ThermoFisher, NP0322BOX) with MES running
buffer (ThermoFisher, NP000202). Proteins were transferred to PVDF membranes
(ThermoFisher, IB24001) using the iBlot2 system and blocked with 5% skim milk
in tris-buffered saline with 0.1% tween-20 (TBST) at 25 °C for 1 h. Membranes
were then washed with TBST (3 × 5min), incubated with primary antibody in
TBST with 5% BSA (1:1000, 4 °C, overnight), washed with TBST (3 × 5min),
incubated with HRP-conjugated secondary antibody in TBST with 2% skim milk
(1:10,000, 25 °C, 1 h), and washed with TBST (2 × 5 min) and TBS (1 × 5 min).
Membranes were visualized using enhanced chemiluminescent reagents (Pierce
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ECL Western blotting substrate, ThermoFisher, 32106) on a syngene PXi4 image
analysis system. Primary antibodies used: acetylated α-tubulin (6-11B-1, sc-23950,
Santa Cruz Biotechnology, Inc), vinculin (E1E9V) XP (13901, Lot: 6, Cell Signaling
Technology), acetyl-histone H3 (K36) (D9T5Q, 27683, Lot: 1, Cell Signaling
Technology), acetyl-histone H3 (K27) (4353, Lot: 1, Cell Signaling Technology).
Secondary antibodies used: Anti-rabbit IgG HRP-linked antibody (Cell Signaling
Technology, CST-7074S), Anti-mouse IgG HRP-linked antibody (Cell Signaling
Technology, CST-7076S). Protein marker used: Precision Plus Protein All Blue
Standard (BioRAD, 161-0373).
Statistics and reproducibility. All measurements considered were taken from
distinct samples. Repeated measurements of a single sample are considered n = 1.
Safety statement. No unexpected or unusually high safety hazards were
encountered.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its supplementary information files. Source data are provided with
this paper.
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